Enhanced tumor retention of radioiodinated anti-epidermal growth factor receptor antibody using novel bifunctional iodination linker for radioimmunotherapy

Eun Jung Kim, Byoung Soo Kim, Dan Bee Choi, Sung-Gil Chi, Tae Hyun Choi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Radioimmunotherapy (RIT) uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target tumor cells. Radioiodine is most commonly employed to prepare radiolabeled proteins (antibodies,peptides) for in vitro and in vivo applications. A major shortcoming of radioiodinated proteins prepared by direct labeling methods is their deiodination in vivo. For the preparation of more stable radioiodinated antibodies,we developed a new linker (N-(4- isothiocyanatobenzyl)-2-(3-(tributylstannyl)phenyl) acetamide (IBPA). This study evaluated the usefulness of IBPA as a linker for the stable radioiodinated internalizing antibody,cetuximab. Directly labeled cetuximab ([125I]-cetuximab) was prepared by the chloramine T method. To prepare indirectly labeled cetuximab using IBPA ([125I]-IBPAcetuximab),IBPA was radioiodinated using chloramine-T to give N-(4-isothiocyanatobenzyl)-2-(3-[125I]phenyl)acetamide ([125I]-IBPA),which was purified by high performance liquid chromatography. [125I]-IBPA was then conjugated to cetuximab. In vitro target binding and internalizing assays were performed in PC9,LS174T,and FaDu cell lines. In vivo planar images were obtained using an Inveon SPECT scanner 3,24,48,and 168 h after i.v. injection of [125I]-cetuximab or [125I]-IBPAcetuximab in athymic mice bearing LS174T tumor xenografts. Specific binding and internalized radioactivity of [125I]-IBPAcetuximab were higher than those of [125I]-cetuximab in PC9,LS174T,and FaDu cell lines. In planar images scant radioactivity was evident in thyroid glands after injection of [125I]-IBPA-cetuximab,while a high level of radioactivity was present in thyroid glands after injection of [125I]-cetuximab. Tumor uptake value of [125I]-IBPA-cetuximab was higher than that of [125I]-cetuximab for up to 168 h. [125I]-IBPA-cetuximab is stable and resistant to deiodination in vivo. IBPA is a promising bi-functional linker for radioiodination of internalizing monoclonal antibodies for in vivo applications including radioimmunotherapy.

Original languageEnglish
Pages (from-to)3159-3168
Number of pages10
JournalOncology Reports
Volume35
Issue number6
DOIs
Publication statusPublished - 2016 Jun 1

Fingerprint

Radioimmunotherapy
Halogenation
Epidermal Growth Factor Receptor
Antibodies
Neoplasms
Radioactivity
Injections
Cetuximab
Thyroid Gland
acetamide
Cell Line
Single-Photon Emission-Computed Tomography
Heterografts
Nude Mice
Radioisotopes
Proteins

Keywords

  • (n-(4-isothiocyanatobenzyl)- 2-(3-(tributylstannyl)phenyl) acetamide (IBPA)
  • Deiodination
  • Radioimmunotherapy
  • Tumor targeting

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Enhanced tumor retention of radioiodinated anti-epidermal growth factor receptor antibody using novel bifunctional iodination linker for radioimmunotherapy. / Kim, Eun Jung; Kim, Byoung Soo; Choi, Dan Bee; Chi, Sung-Gil; Choi, Tae Hyun.

In: Oncology Reports, Vol. 35, No. 6, 01.06.2016, p. 3159-3168.

Research output: Contribution to journalArticle

@article{7f292526de0243bca6f3906ac26fb10d,
title = "Enhanced tumor retention of radioiodinated anti-epidermal growth factor receptor antibody using novel bifunctional iodination linker for radioimmunotherapy",
abstract = "Radioimmunotherapy (RIT) uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target tumor cells. Radioiodine is most commonly employed to prepare radiolabeled proteins (antibodies,peptides) for in vitro and in vivo applications. A major shortcoming of radioiodinated proteins prepared by direct labeling methods is their deiodination in vivo. For the preparation of more stable radioiodinated antibodies,we developed a new linker (N-(4- isothiocyanatobenzyl)-2-(3-(tributylstannyl)phenyl) acetamide (IBPA). This study evaluated the usefulness of IBPA as a linker for the stable radioiodinated internalizing antibody,cetuximab. Directly labeled cetuximab ([125I]-cetuximab) was prepared by the chloramine T method. To prepare indirectly labeled cetuximab using IBPA ([125I]-IBPAcetuximab),IBPA was radioiodinated using chloramine-T to give N-(4-isothiocyanatobenzyl)-2-(3-[125I]phenyl)acetamide ([125I]-IBPA),which was purified by high performance liquid chromatography. [125I]-IBPA was then conjugated to cetuximab. In vitro target binding and internalizing assays were performed in PC9,LS174T,and FaDu cell lines. In vivo planar images were obtained using an Inveon SPECT scanner 3,24,48,and 168 h after i.v. injection of [125I]-cetuximab or [125I]-IBPAcetuximab in athymic mice bearing LS174T tumor xenografts. Specific binding and internalized radioactivity of [125I]-IBPAcetuximab were higher than those of [125I]-cetuximab in PC9,LS174T,and FaDu cell lines. In planar images scant radioactivity was evident in thyroid glands after injection of [125I]-IBPA-cetuximab,while a high level of radioactivity was present in thyroid glands after injection of [125I]-cetuximab. Tumor uptake value of [125I]-IBPA-cetuximab was higher than that of [125I]-cetuximab for up to 168 h. [125I]-IBPA-cetuximab is stable and resistant to deiodination in vivo. IBPA is a promising bi-functional linker for radioiodination of internalizing monoclonal antibodies for in vivo applications including radioimmunotherapy.",
keywords = "(n-(4-isothiocyanatobenzyl)- 2-(3-(tributylstannyl)phenyl) acetamide (IBPA), Deiodination, Radioimmunotherapy, Tumor targeting",
author = "Kim, {Eun Jung} and Kim, {Byoung Soo} and Choi, {Dan Bee} and Sung-Gil Chi and Choi, {Tae Hyun}",
year = "2016",
month = "6",
day = "1",
doi = "10.3892/or.2016.4706",
language = "English",
volume = "35",
pages = "3159--3168",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Enhanced tumor retention of radioiodinated anti-epidermal growth factor receptor antibody using novel bifunctional iodination linker for radioimmunotherapy

AU - Kim, Eun Jung

AU - Kim, Byoung Soo

AU - Choi, Dan Bee

AU - Chi, Sung-Gil

AU - Choi, Tae Hyun

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Radioimmunotherapy (RIT) uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target tumor cells. Radioiodine is most commonly employed to prepare radiolabeled proteins (antibodies,peptides) for in vitro and in vivo applications. A major shortcoming of radioiodinated proteins prepared by direct labeling methods is their deiodination in vivo. For the preparation of more stable radioiodinated antibodies,we developed a new linker (N-(4- isothiocyanatobenzyl)-2-(3-(tributylstannyl)phenyl) acetamide (IBPA). This study evaluated the usefulness of IBPA as a linker for the stable radioiodinated internalizing antibody,cetuximab. Directly labeled cetuximab ([125I]-cetuximab) was prepared by the chloramine T method. To prepare indirectly labeled cetuximab using IBPA ([125I]-IBPAcetuximab),IBPA was radioiodinated using chloramine-T to give N-(4-isothiocyanatobenzyl)-2-(3-[125I]phenyl)acetamide ([125I]-IBPA),which was purified by high performance liquid chromatography. [125I]-IBPA was then conjugated to cetuximab. In vitro target binding and internalizing assays were performed in PC9,LS174T,and FaDu cell lines. In vivo planar images were obtained using an Inveon SPECT scanner 3,24,48,and 168 h after i.v. injection of [125I]-cetuximab or [125I]-IBPAcetuximab in athymic mice bearing LS174T tumor xenografts. Specific binding and internalized radioactivity of [125I]-IBPAcetuximab were higher than those of [125I]-cetuximab in PC9,LS174T,and FaDu cell lines. In planar images scant radioactivity was evident in thyroid glands after injection of [125I]-IBPA-cetuximab,while a high level of radioactivity was present in thyroid glands after injection of [125I]-cetuximab. Tumor uptake value of [125I]-IBPA-cetuximab was higher than that of [125I]-cetuximab for up to 168 h. [125I]-IBPA-cetuximab is stable and resistant to deiodination in vivo. IBPA is a promising bi-functional linker for radioiodination of internalizing monoclonal antibodies for in vivo applications including radioimmunotherapy.

AB - Radioimmunotherapy (RIT) uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target tumor cells. Radioiodine is most commonly employed to prepare radiolabeled proteins (antibodies,peptides) for in vitro and in vivo applications. A major shortcoming of radioiodinated proteins prepared by direct labeling methods is their deiodination in vivo. For the preparation of more stable radioiodinated antibodies,we developed a new linker (N-(4- isothiocyanatobenzyl)-2-(3-(tributylstannyl)phenyl) acetamide (IBPA). This study evaluated the usefulness of IBPA as a linker for the stable radioiodinated internalizing antibody,cetuximab. Directly labeled cetuximab ([125I]-cetuximab) was prepared by the chloramine T method. To prepare indirectly labeled cetuximab using IBPA ([125I]-IBPAcetuximab),IBPA was radioiodinated using chloramine-T to give N-(4-isothiocyanatobenzyl)-2-(3-[125I]phenyl)acetamide ([125I]-IBPA),which was purified by high performance liquid chromatography. [125I]-IBPA was then conjugated to cetuximab. In vitro target binding and internalizing assays were performed in PC9,LS174T,and FaDu cell lines. In vivo planar images were obtained using an Inveon SPECT scanner 3,24,48,and 168 h after i.v. injection of [125I]-cetuximab or [125I]-IBPAcetuximab in athymic mice bearing LS174T tumor xenografts. Specific binding and internalized radioactivity of [125I]-IBPAcetuximab were higher than those of [125I]-cetuximab in PC9,LS174T,and FaDu cell lines. In planar images scant radioactivity was evident in thyroid glands after injection of [125I]-IBPA-cetuximab,while a high level of radioactivity was present in thyroid glands after injection of [125I]-cetuximab. Tumor uptake value of [125I]-IBPA-cetuximab was higher than that of [125I]-cetuximab for up to 168 h. [125I]-IBPA-cetuximab is stable and resistant to deiodination in vivo. IBPA is a promising bi-functional linker for radioiodination of internalizing monoclonal antibodies for in vivo applications including radioimmunotherapy.

KW - (n-(4-isothiocyanatobenzyl)- 2-(3-(tributylstannyl)phenyl) acetamide (IBPA)

KW - Deiodination

KW - Radioimmunotherapy

KW - Tumor targeting

UR - http://www.scopus.com/inward/record.url?scp=84964823556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964823556&partnerID=8YFLogxK

U2 - 10.3892/or.2016.4706

DO - 10.3892/or.2016.4706

M3 - Article

VL - 35

SP - 3159

EP - 3168

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 6

ER -